MedPath

Investigation on the procedure of water loading test in Japanese healthy male volunteers

Not Applicable
Conditions
urological diseases
Registration Number
JPRN-UMIN000016272
Lead Sponsor
Medical Co. LTA Sumida Hospital
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
Male
Target Recruitment
48
Inclusion Criteria

Not provided

Exclusion Criteria

(1)Subject with present illness. (2)Subject who has past medical history judged by investigator as an influence evaluate subject safety. (e.g. liver diseases, kidney diseases, cardiovascular diseases, hematologic diseases, endocrine system diseases, diseases of digestive system, diseases of respiratory system, infectious diseases, etc.) (3)Subject with diseases which possibly influence release and/or absorption of study drug ingredients. (4)Serum Na <137 mEq/L at screening test or a day before study drug administration. (5)Urination speed 0.12mL/kg/min from -30min to the time just before the study drug administration. (6)Subject had nausea and/or vomiting with water loading test at pre dosing. (7)History or presence of drug and/or alcohol dependence. (8) History or presence of drug allergy. (9) History or presence of food allergy. (10)Subject who take alcohol =>20g/day. (11)Dosing of any drug or supplements within 2 weeks prior to study drug administration. (12)Subject who smoked after screening test. (13)Subject who took food or beverages containing grapefruit (juice, flesh) within 3 days prior to study drug administration. (14)Use of other study drug for other clinical study within 12 weeks prior to study drug administration. (15)Subject who participated in other clinical study for medical devices within 12 weeks prior to study drug administration. (16) Subject who donated more than 400ml or 200ml of blood within 12 weeks or 4 weeks respectively, or component blood within 2 weeks prior to study drug administration, respectively. (17)Subject with positive test results of HIV antigen/antibody, HBs antigen, HCV antibody and/or syphilis. (18) Subject who are considered to be inadequate for this study by investigator.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath